163 related articles for article (PubMed ID: 24431897)
1. Amelioration of carbon tetrachloride-induced cirrhosis and portal hypertension in rat using adenoviral gene transfer of Akt.
Deng G; Huang XJ; Luo HW; Huang FZ; Liu XY; Wang YH
World J Gastroenterol; 2013; 19(43):7778-87. PubMed ID: 24431897
[TBL] [Abstract][Full Text] [Related]
2. [Akt gene therapy for cirrhotic rats with portal hypertension].
Huang FZ; Deng G; Liu XY; Luo CQ
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Jan; 33(1):31-7. PubMed ID: 18245901
[TBL] [Abstract][Full Text] [Related]
3. Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats.
Morales-Ruiz M; Cejudo-Martín P; Fernández-Varo G; Tugues S; Ros J; Angeli P; Rivera F; Arroyo V; Rodés J; Sessa WC; Jiménez W
Gastroenterology; 2003 Aug; 125(2):522-31. PubMed ID: 12891555
[TBL] [Abstract][Full Text] [Related]
4. Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.
Zhang CG; Zhang B; Deng WS; Duan M; Chen W; Wu ZY
World J Gastroenterol; 2016 May; 22(18):4484-500. PubMed ID: 27182159
[TBL] [Abstract][Full Text] [Related]
5. Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model.
Theodorakis NG; Wang YN; Wu JM; Maluccio MA; Sitzmann JV; Skill NJ
Am J Physiol Gastrointest Liver Physiol; 2009 Oct; 297(4):G792-9. PubMed ID: 19628654
[TBL] [Abstract][Full Text] [Related]
6. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats.
Coll M; Rodriguez S; Raurell I; Ezkurdia N; Brull A; Augustin S; Guardia J; Esteban R; Martell M; Genescà J
Hepatology; 2012 Nov; 56(5):1849-60. PubMed ID: 22610782
[TBL] [Abstract][Full Text] [Related]
7. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
Hu L; Su L; Dong Z; Wu Y; Lv Y; George J; Wang J
J Mol Med (Berl); 2019 Mar; 97(3):423-434. PubMed ID: 30721324
[TBL] [Abstract][Full Text] [Related]
8. Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction.
Xu W; Lu C; Zhang F; Shao J; Yao S; Zheng S
FEBS J; 2017 Jan; 284(1):114-133. PubMed ID: 27896916
[TBL] [Abstract][Full Text] [Related]
9. Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension.
Laviña B; Gracia-Sancho J; Rodríguez-Vilarrupla A; Chu Y; Heistad DD; Bosch J; García-Pagán JC
Gut; 2009 Jan; 58(1):118-25. PubMed ID: 18829979
[TBL] [Abstract][Full Text] [Related]
10. Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo.
Fallowfield JA; Hayden AL; Snowdon VK; Aucott RL; Stutchfield BM; Mole DJ; Pellicoro A; Gordon-Walker TT; Henke A; Schrader J; Trivedi PJ; Princivalle M; Forbes SJ; Collins JE; Iredale JP
Hepatology; 2014 Apr; 59(4):1492-504. PubMed ID: 23873655
[TBL] [Abstract][Full Text] [Related]
11. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
Klein S; Rick J; Lehmann J; Schierwagen R; Schierwagen IG; Verbeke L; Hittatiya K; Uschner FE; Manekeller S; Strassburg CP; Wagner KU; Sayeski PP; Wolf D; Laleman W; Sauerbruch T; Trebicka J
Gut; 2017 Jan; 66(1):145-155. PubMed ID: 26385087
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
[TBL] [Abstract][Full Text] [Related]
13. A new model of portal vein thrombosis in rats with cirrhosis induced by partial portal vein ligation plus carbon tetrachloride and intervened with rivaroxaban.
Guo Y; Dong S; Li M; Tao Y; Lv J; Liu C
BMC Gastroenterol; 2024 May; 24(1):161. PubMed ID: 38741060
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure.
Theodorakis NG; Wang YN; Korshunov VA; Maluccio MA; Skill NJ
World J Gastroenterol; 2015 Apr; 21(14):4126-35. PubMed ID: 25892862
[TBL] [Abstract][Full Text] [Related]
15. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
[TBL] [Abstract][Full Text] [Related]
16. Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl
Zhang R; Chen J; Liu D; Wang Y
Front Med; 2019 Jun; 13(3):398-408. PubMed ID: 30820806
[TBL] [Abstract][Full Text] [Related]
17. Soluble epoxide hydrolase inhibition with t-TUCB alleviates liver fibrosis and portal pressure in carbon tetrachloride-induced cirrhosis in rats.
Zhang CH; Zheng L; Gui L; Lin JY; Zhu YM; Deng WS; Luo M
Clin Res Hepatol Gastroenterol; 2018 Apr; 42(2):118-125. PubMed ID: 29031875
[TBL] [Abstract][Full Text] [Related]
18. Deleterious effects of silymarin on the expression of genes controlling endothelial nitric oxide synthase activity in carbon tetrachloride-treated rat livers.
Cho YK; Yun JW; Park JH; Kim HJ; Park DI; Sohn CI; Jeon WK; Kim BI; Jin W; Kwon YH; Shin MK; Yoo TM; Kang JH; Park CS
Life Sci; 2009 Aug; 85(7-8):281-90. PubMed ID: 19527736
[TBL] [Abstract][Full Text] [Related]
19. Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension.
Mookerjee RP; Mehta G; Balasubramaniyan V; Mohamed Fel Z; Davies N; Sharma V; Iwakiri Y; Jalan R
J Hepatol; 2015 Feb; 62(2):325-31. PubMed ID: 25152204
[TBL] [Abstract][Full Text] [Related]
20. Defective endothelial nitric oxide synthase signaling is mediated by rho-kinase activation in rats with secondary biliary cirrhosis.
Anegawa G; Kawanaka H; Yoshida D; Konishi K; Yamaguchi S; Kinjo N; Taketomi A; Hashizume M; Shimokawa H; Maehara Y
Hepatology; 2008 Mar; 47(3):966-77. PubMed ID: 18167063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
